Preview

Пульмонология

Расширенный поиск

Надежды и ожидания от современной фармакотерапии больных хронической обструктивной болезнью легких: исследование UPLIFT

https://doi.org/10.18093/0869-0189-2009-0-1-102-110

Полный текст:

Об авторе

А. Н. Цой
Московская медицинская академия им. И.М.Сеченова
Россия

Цой Алла Николаевна – д. м. н., проф. кафедры клинической фармакологии и пропедевтики внутренних болезней  

119991, Москва, ул. Трубецкая, 8, стр. 2

тел.: (495) 915-39-01



Список литературы

1. Jemal A., Ward E., Hao Y. et al. Trends in the leading causes of death in the United States, 1970–2002. J. A. M. A. 2005; 294: 1255–1259.

2. GOLD. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Update 2006. Available at: http://www.goldcopd.org/GuidelinesResources.asp?l1=2&l2=0.

3. Garcia-Ayremick J., Farrero E., Felez M.A. et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100–105.

4. Antonelli Incalzi R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794–2800.

5. Suissa S., McGhan R., Niewoehner D., Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007; 4 (7): 535–542.

6. Quassem A., Snow V., Shekelle P. et at. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American college of physicians. Ann. Inter. Med. 2007; 147 (9): 633–638.

7. Gartlehner G., Hansen R.A., Carsson S.S. et al. Efficacy and safety of inhaled corticosteroids in pateints with COPD: A systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 2006; 4 (3): 253–262.

8. Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive lung disease. N. Engl. J. Med. 2000; 343: 1902–1909.

9. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948–1953.

10. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.

11. Vincken W., van Noord J.A., Greefborst A.P.M. et al. Improved helth outcomes in patiens COPD during 1 yr,s treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.

12. Anzuetto A., Tashkin D., Menjoge S. et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmac. Ther. 2005; 18: 75–81.

13. Tonnel A.B., Perz T., Grosbois J.M. et al. Improvement in HRQoL of COPD patients after 9 months′s treatment with tiotropium bromide: use of a new scale for daily medical practice. Eur. Respir. J. 2005; 26: 290s.

14. Cassaburi R., Mahler D.A., Jones P.W. et al. Long-term evalution of once-daily inhaled dosing with tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.

15. Dusser D., Bravo M.-L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27 (5): 1076.

16. Tashkin D.P., Celli B., Seen S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.

17. American Thoracic Society. Standartisation of spirometry; 1994 update. Am. J. Respir. Crit. Care Med. 1995; 152: 1107–1136.

18. Tashkin D.P., Celli B., Decramer M. et al. Bronchodilator resposiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.

19. Celli B., Decramer M., Tashkin D. et al. Differences in baseline FEV1 and tobacco use in COPD patients from different racial subgroups. In: Proceedings of the ATS Intern Conference. San Francisco; 2007. Abs. 849.

20. Tashkin D.P., Celli B., Decramer M. et al. Prescribing patterns according to COPD treatment guideline in patients enrolled in a global clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 274.

21. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332–338.

22. Decramer M., Celli B., Tashkin D. et al. Regional differences in the treatment of patients with moderate COPD in a global clinical trial. In: 16th Annual congress of ERS 2006. Munich; 2006.

23. Decramer M., Tashkin D.P., Celli B. et al. Predictors exacerbations of COPD in a large global clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 271.

24. Celli B., Decramer M., Tashkin D.P. et al. Predictors of mortality in a large global CPD clinical trial. In: Proceedings of the ATS International Conference. San Diego; 2006. Abs. 726.

25. Kesten S.F., Jara M., Wenrworth C., Lapes S. Pooled clinical trial analysis of the safety of the tiotropium. Chest 2006; 130: 1695–1703.


Для цитирования:


Цой А.Н. Надежды и ожидания от современной фармакотерапии больных хронической обструктивной болезнью легких: исследование UPLIFT. Пульмонология. 2009;(1):102-110. https://doi.org/10.18093/0869-0189-2009-0-1-102-110

For citation:


Tsoy A.N. Future directions of pharmacotherapy of chronic obstructive pulmonary disease: the UPLIFT trial. PULMONOLOGIYA. 2009;(1):102-110. (In Russ.) https://doi.org/10.18093/0869-0189-2009-0-1-102-110

Просмотров: 69


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)